上海华理生物医药股份有限公司成立于2005年，是一家以药物研发为基础，聚焦于小分子新药发现和原料药合成工艺开发，并为国内外药企提供研发和技术服务的高新技术企业。在药物发现领域，公司以构效关系研究为基础，通过计算机辅助设计对天然抗肿瘤活性分子进行结构优化和修饰，已获得安全有效的小分子抗肿瘤靶向药物，形成拥有自主知识产权的新药管线。在药物合成领域，公司深耕近二十年，拥有数十项药物合成专利。其中多项专利技术被国内多家著名制药企业采用，相关产品（如吉非罗齐和甲基多巴）的销售额处于世界领先地位。近年来公司专注于研发催化技术、绿色氟代技术和连续流反应技术，致力于为客户提供绿色高效的制药合成技术，应用于重大医药原料及其中间体的生产。

Shanghai Ecust Biomedicine Co., Ltd., established in 2005, is a high-tech enterprise focused on small molecule drug discovery and API synthesis process development, providing R&D and technical services to domestic and international pharmaceutical companies.

In drug discovery, the company employs structure-activity relationship studies and computer-aided design to optimize natural anti-tumor compounds, developing safe and effective small molecule targeted cancer therapeutics with proprietary intellectual property rights.

In pharmaceutical synthesis, the company has nearly two decades of expertise and holds dozens of synthesis patents. Several patented technologies have been adopted by major domestic pharmaceutical manufacturers, with related products (e.g. Gemfibrozil and Methyldopa) achieving world-leading sales. The company specializes in catalytic technologies, green fluorination, and continuous flow reaction technologies, providing environmentally sustainable synthesis solutions for pharmaceutical raw materials and intermediates production.